In a last step of our data mining effort, we took advantage of our established gene signatures of TH-MYCN+/+ versus wild-type mice 6 weeks after birth together with previously validated bioinformatics pipelines to infer small regulatory modules driven by master regulator transcription factors that could uncover novel tumor-specific vulnerabilities for innovative therapeutic approaches (Figure 2D). The gene discussed is MYCN; the disease is neoplasm.